TCTR20171016001已完成4 期
Immunogenicity and Safety of WHO-Approved TRC-ID Regimen with a Chromatographically Purified Vero Cell Rabies Vaccine with or without Rabies Immunoglobulin in Children
iaoning Cheng Da Biotechnology Company in China.0 个研究点目标入组 45 人开始时间: 2017年10月16日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 1 Years 至 15 Years（—）
- 性别
- All
入选标准
- •All participants are included in the study will be evaluated by a physician prior to enrollment in the study. Participants or patients meet the inclusion criteria if they are 1-15 years and give signed informed consent from their parents, willing to participate in this study and be able to receive the vaccination and collect blood sample as the study plan.
排除标准
- •They will be excluded if they have prior history of rabies vaccination or any equine/human serum administration such as snake antivenom and tetanus antiserum or vaccine allergy, Persons who have immunosuppressive conditions such as known HIV infection, transplantation, chronic renal failure, receiving of steroid or immunosuppressive drugs were excluded, person received anti-malarial drugs within the previous two months or any blood products within previous three months were excluded. Urine pregnancy test must be done in all female adolescents to exclude the pregnancy in first visit.
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac® for the season 2009/2010. An open-label, baseline-controlled multi-center study in two groups: adult subjects =18 and =60 years and elderly subjects =61 years of age. - Influvac Annual Update 2009/2010EUCTR2009-010900-27-DESolvay Biologicals BV120
进行中（未招募）
不适用
Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac® for the season 2009/2010. An open-label, baseline-controlled multi-center study in two groups: adult subjects =18 and =60 years and elderly subjects =61 years of age. - Influvac Annual Update 2009/2010Prophylaxis of InfluenzaMedDRA version: 9.1Level: HLTClassification code 10022005Term: Influenza viral infectionsEUCTR2009-010900-27-BESolvay Biologicals BV120
进行中（未招募）
不适用
Safety, clinical tolerability and immune activity of increasing doses of the investigational medicinal product gpASIT+TM administered under the skin to patients suffering from hay fever.Treatment of seasonal grass pollen rhinoconjunctivitis.MedDRA version: 15.1Level: LLTClassification code 10019170Term: Hay feverSystem Organ Class: 100000004870EUCTR2013-000056-18-DEBioTech Tools S.A.
进行中（未招募）
1 期
Clinical study with a new medication (grass pollen - ASIT+TM or gpASIT+TM) administered subcutaneously with or without the new immunoregulating agent (DnaK) for the treatment of hay fever.EUCTR2011-004486-33-BEBioTech Tools S.A.
招募中
1 期
A study to Evaluate Immunogenicity, Safety and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2COVID-19 diseaseMedDRA version: 23.1Level: PTClassification code 10084457Term: COVID-19 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-005504-36-DKBavarian Nordic A/S4,000